Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.55 |
| ▸ | TP53 | P04637 | 3/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | MAOB | P27338 | 4/20 | 0.50 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.48 |
| ▸ | SHMT2 | P34897 | 1/20 | 0.47 |
| ▸ | CA12 | O43570 | 5/20 | 0.47 |
| ▸ | CA9 | Q16790 | 5/20 | 0.47 |
| ▸ | CA2 | P00918 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | HTT | P42858 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5209506 | 0.86 | CCR2 (0.46) | MAPTTP53LMNAMAOBALOX5 | |
| SCHEMBL5207946 | 0.85 | MAPT (0.49) | MAPTTP53LMNAMAOBALOX5 | |
| SCHEMBL24229499 | 0.84 | NR1H4 (0.49) | MAPTLMNAMAOBALOX5SHMT2 | |
| SCHEMBL8545651 | 0.84 | MAPT (0.55) | MAPTTP53LMNAMAOBALOX5 | |
| SCHEMBL5858926 | 0.83 | SHMT2 (0.47) | MAPTTP53LMNAMAOBSHMT2 | |
| SCHEMBL11526406 | 0.83 | CA12 (0.66) | MAPTTP53LMNAMAOBSHMT2 | |
| SCHEMBL416748 | 0.82 | MAPT (0.56) | MAPTTP53LMNAMAOBALOX5 | |
| SCHEMBL30529047 | 0.79 | CA12 (0.62) | MAPTTP53LMNAMAOBALOX5 | |
| SCHEMBL2738436 | 0.79 | CA12 (0.62) | MAPTTP53LMNAMAOBALOX5 | |
| SCHEMBL5860032 | 0.79 | CA12 (0.45) | MAPTLMNAMAOBSHMT2CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11485708-B2 | Compounds for treatment of PD-L1 diseases | CHEMOCENTRYX, INC. (US) | 2022-11-01 | — | — | US | disclosed |
| US-20210002229-A1 | COMPOUNDS FOR TREATMENT OF PD-L1 DISEASES | CHEMOCENTRYX, INC. | 2021-01-07 | — | — | US | disclosed |
| WO-2020257549-A2 | COMPOUNDS FOR TREATMENT OF PD-L1 DISEASES | CHEMOCENTRYX, INC. (US) | 2020-12-24 | — | — | WO | disclosed |
| US-8921360-B2 | Heterobicycle-substituted azolyl benzene fungicides | E. I. DU PONT DE NEMOURS AND COMPANY | 2014-12-30 | — | — | US | disclosed |
| EP-2493880-B1 | HETEROBICYCLE-SUBSTITUTED AZOLYL BENZENE FUNGICIDES | DU PONT (US) | 2013-09-18 | — | — | EP | disclosed |
| EP-2493880-A1 | HETEROBICYCLE-SUBSTITUTED AZOLYL BENZENE FUNGICIDES | E. I. du Pont de Nemours and Company (US) | 2012-09-05 | — | — | EP | disclosed |
| US-20120202815-A1 | HETEROBICYCLE-SUBSTITUTED AZOLYL BENZENE FUNGICIDES | E.I.DU PONT DE NEMOURS AND COMPANY (US) | 2012-08-09 | — | — | US | disclosed |
| WO-2011059619-A1 | HETEROBICYCLE-SUBSTITUTED AZOLYL BENZENE FUNGICIDES | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2011-05-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120202815-A1 | HETEROBICYCLE-SUBSTITUTED AZOLYL BENZENE FUNGICIDES | CBR3, CBR1, CYP2S1 | MAPT 4549/4885TP53 3681/4885LMNA 4756/4885 |
| US-20210002229-A1 | COMPOUNDS FOR TREATMENT OF PD-L1 DISEASES | CD274, PDCD1, PDCD1LG2 | MAPT 3250/4885TP53 74/4885LMNA 688/4885 |
| US-11485708-B2 | Compounds for treatment of PD-L1 diseases | CD274, PDCD1, PDCD1LG2 | MAPT 3250/4885TP53 74/4885LMNA 688/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.